Moncef Slaoui is the Chairman of Vaccines and has been responsible for the global vaccines business through its integration of the Novartis vaccine acquisition in 2015. Prior to his current role, Moncef served as Chairman, GSK R&D for eight years.
During his tenure at GSK, Moncef has also had responsibility for the franchise commercial organisation, focused on new product launches and lifecycle management. He continues to oversee GSK’s venture capital arm, SR One, and other venture capital partnerships, as well as its groundbreaking Bioelectronics R&D strategy.
He is a member of the Corporate Executive Team and Board of Directors.
In his position as Chairman, R&D, Moncef spearheaded a profound overhaul of GSK’s pharmaceutical R&D, resulting in a substantial improvement in productivity, with a late-stage pipeline comprising more than 30 Phase III programmes and a totally redesigned discovery organisation comprising 38 highly focused and accountable Discovery Performance Units.
In his role as leader of the Franchise Commercial Operation, he spearheaded a deep transformation of GSK’s launch and commercial strategy capabilities.
In his previous position in GSK Biologicals, he engineered the development of a robust vaccines pipeline, including Rotarix to prevent infantile gastroenteritis, Synflorix to prevent Pneumococcal disease and Cervarix to prevent cervical cancer.
Moncef earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston.
He was a professor of Immunology at the University of Mons, Belgium. He has authored more than 100 scientific papers and presentations and is a member of the PhRMA Foundation Board of Directors, Advisory Board of Qatar Foundation, National Institutes of Health Advisory Committee to the Director, and the Biotechnology Industry Organization Board of Directors. A citizen of Morocco, Belgium and the USA, he is fluent in English, French and Arabic.